Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;12(7):7795-7800.
doi: 10.1002/cam4.5537. Epub 2022 Dec 30.

Antigen rapid diagnostic test monitoring for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients: Is it cost-effective?

Mario Caccese  1 , Anna Maria Saieva  2 , Valentina Guarneri  3   4 , Sara Lonardi  5 , Massimo Cacco  6 , Vanna Chiarion Sileni  7 , Michele Gottardi  8 , Eleonora Mioranza  3 , Francesca Bergamo  1 , Antonella Brunello  1 , Vittorina Zagonel  1 , Patrizia Benini  9
Affiliations

Antigen rapid diagnostic test monitoring for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients: Is it cost-effective?

Mario Caccese et al. Cancer Med. 2023 Apr.

Abstract

Background: Routine testing for cancer patients not presenting COVID-19-related symptoms and fully vaccinated for SARS-CoV-2 prior to cancer treatment is controversial.

Methods: In this retrospective study we evaluated whether antigen-rapid-diagnostic-test (Ag-RDT) monitoring for SARS-CoV-2 in a large cohort of consecutive asymptomatic (absence of SARS-CoV-2-related symptoms such as fever, cough, sore throat or nasal congestion) and fully vaccinated cancer patients enrolled in a short period during cancer treatment has an impact on the therapeutic path of cancer patients.

Results: From December 27, 2021, to February 11, 2022, 2439 cancer patients were screened through Ag-RDT for SARS-CoV-2 before entering the hospital for systemic treatment. Fifty-three patients (2.17%) tested positive, of whom 7 (13.2%) subsequently developed COVID-related symptoms, generally mild. Cancer treatment was discontinued, as a precaution, in 49 patients (92.5%) due to the test positivity.

Conclusion: SARS-CoV-2 screening in asymptomatic and fully vaccinated cancer patients during systemic treatment appeared to be not cost-effective: the low rate of SARS-CoV-2 positive patients and the low percentage of overt associated infection do not seem proportional to the direct costs (nursing work for swabs, costs of materials and patient monitoring) and indirect costs (dedicated rooms, extension of waiting times for patients and oncologists in delivering therapy as well as its discontinuation in the positive ones). It can, on the other hand, be detrimental when systemic cancer treatment is suspended as a precaution. Given the small number of patients testing positive and the rapid and favorable trend of the infection, it is recommended to always consider continuing systemic oncological treatment, especially when this impacts patient survival as in the adjuvant or neoadjuvant setting.

Keywords: COVID-19; SARS-CoV-2; antigen-rapid-diagnostic test; cancer patients.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflicts of interest.

References

    1. Obeid M, Suffiotti M, Pellaton C, et al. Humoral responses against variants of concern by COVID‐19 mRNA vaccines in immunocompromised patients. JAMA Oncol. 2022;8(5):e220446. Available from. https://jamanetwork.com/journals/jamaoncology/fullarticle/2790203 - PMC - PubMed
    1. Giuliano AR, Lancet JE, Pilon‐Thomas S, et al. Evaluation of antibody response to SARS‐CoV‐2 mRNA‐1273 vaccination in patients with cancer in Florida. JAMA Oncol. 2022;8(5):748‐754. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2790099 - PMC - PubMed
    1. Javadinia SA, Ariamanesh M, Nabavifard M, et al. Multicenter study of antibody seroprevalence against COVID‐19 in patients presenting to Iranian cancer centers after one year of the COVID‐19 pandemic. Cancer Invest. 2022;40(2):115‐123. - PubMed
    1. Guven DC, Sahin TK, Kilickap S, Uckun FM. Antibody responses to COVID‐19 vaccination in cancer: a systematic review. Front Oncol. 2021;11:759108. - PMC - PubMed
    1. Mair MJ, Berger JM, Mitterer M, et al. Third dose of SARS‐CoV‐2 vaccination in hemato‐oncological patients and health care workers: immune responses and adverse events—a retrospective cohort study. Eur J Cancer. 2022;165:184‐194. - PMC - PubMed

Publication types